Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis
Authors:
Open Access
- 19 February 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1352975
Abstract
Introduction: Vulvar cancer carries a favourable prognosis in early stages. However, therapeutic options for advanced or recurrent cases are limited despite a variety of therapeutic modalities, such as extensive surgical resection, chemotherapy, and radiotherapy. The most important emerging treatment modalities are immune checkpoint inhibitors. This systematic review and meta-analysis aims to assess the efficacy and safety of pembrolizumab, an immune checkpoint inhibitor, in women with advanced vulvar cancer.Materials and methods: Following a comprehensive search, review, and appraisal, two relevant single-arm studies were included. Meta-analysis was conducted using R4.3.0 software and RStudio 2023.03.0, presenting the overall effect size with a 95% confidence interval. Heterogeneity was assessed using I2 and the Cochrane Q χ2 statistics.Results: Out of 154 studies screened for eligibility, two single-arm studies involving 119 patients receiving pembrolizumab for advanced vulvar cancer were included. The pooled objective response rate (ORR) was overall 10% (95% CI: 0.00-0.84) and 9% (95% CI: 0.00-0.89) in the PD-L1 positive subgroup. In the intention-to-treat (ITT) population, 31% (95% CI: 0.04-0.85) exhibited any clinical benefit (complete response, partial response, or stable disease). In the ITT population at six months, progression-free survival (PFS) was 19% (95% CI: 0.01-0.82), and overall survival (OS) was 48% (95% CI: 0.08-0.90). At 12 months, PFS decreased to 9% (95% CI: 0.00-0.85), and OS was 33% (95% CI: 0.04-0.85). No statistically significant heterogeneity was observed in PFS and OS analyses.Discussion and conclusion: This study suggests that one-third of women with advanced or recurrent vulvar cancer may, without the influence of PD-L1 status, benefit from pembrolizumab treatment despite a decline in both PFS and OS at 12 months. These findings provide support for considering pembrolizumab in the treatment paradigm for this specific subset of cancer patients.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023391888Keywords
This publication has 39 references indexed in Scilit:
- Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4Nature Communications, 2023
- Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trialNature Communications, 2023
- Prevalence of human papillomavirus DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysisThe Lancet Oncology, 2023
- Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyGynecologic Oncology, 2022
- Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinomaVirchows Archiv, 2020
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialThe Lancet Respiratory Medicine, 2019
- Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervixLaboratory Investigation, 2016
- Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancersLaboratory Investigation, 2015
- Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulvaEuropean Journal of Cancer, 2013
- E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class IInternational Journal of Cancer, 2004